MedTrace Logo

Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients

NCT05619562 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 166

Last updated 2022-11-17

No results posted yet for this study

Summary

To determine whether the presence of circulating/disseminated tumour cells (CTCs/DTCs) in the blood and bone marrow of the resectable lung cancer (NSCLC) patients is a negative prognostic factor, and to find correlations with other clinical/pathological disease characteristics.

Conditions

  • Non Small Cell Lung Cancer
  • Circulating Tumor Cell

Interventions

DIAGNOSTIC_TEST

Device for CTC/DTC detection

The CTCs/DTCs will be detected and counted in peripheral blood, tumour draining blood and bone marrow samples.

Sponsors & Collaborators

  • The Institute of Molecular and Translational Medicine, Czech Republic

    lead OTHER

Principal Investigators

  • Marian Hajduch, MD, PhD · Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2013-04-30
Completion
2015-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05619562 on ClinicalTrials.gov